Neoadjuvant treatment with trastuzumab and pertuzumab plus fulvestrant in older patients with HER2-positive, ER-positive early breast cancer.

被引：0

作者：

Celis, Juan Jose ^{[1
]}

Rodriguez, Vanessa ^{[1
]}

Rodriguez, Crismar ^{[1
]}

机构：

[1] Soc Anticancerosa Venezuela, Caracas, Venezuela

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 23_SUPPL期

关键词：

D O I：

10.1200/JCO.2024.42.23_suppl.13

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：13 / 13

页数：1

共 50 条

[21] Transcriptional expression of Bcl-2 as predictive of response to neoadjuvant chemotherapy with trastuzumab in HER2-positive ER-positive breast cancer patients.
Tanioka, Maki
Sakai, Kazuko
Sudo, Tamotsu
Sakuma, Toshiko
Hirokaga, Kouichi
Takao, Shintaro
Minami, Hironobu
Negoro, Shunichi
Nakagawa, Kazuhiko
Nishio, Kazuto
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[22] The Effect of Adding Pertuzumab to Adjuvant Trastuzumab in Early HER2-Positive Breast Cancer
Al-Azawi, Ahmed
Hneua, Riyadh Abd-Alrasool
Hameed, Rana Majeed
Hassan, Duha Maithem
JOURNAL OF CONTEMPORARY MEDICAL SCIENCES, 2023, 9 (03): : 197 - 200
[23] A historical controlled study of domestic trastuzumab and pertuzumab in combination with docetaxel for the neoadjuvant treatment of early HER2-positive breast cancer
Xu, Dongdong
Wu, Jiang
Yu, Jing
Yang, Yuqing
Wen, Xinxin
Yang, Jixin
Wei, Hongliang
Xu, Xiaolong
Li, Yike
Yang, Liu
Wang, Lei
Wang, Yijia
Ma, Wen
Li, Nanlin
FRONTIERS IN ONCOLOGY, 2024, 14
[24] Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Swain, Sandra M.
Baselga, Jose
Kim, Sung-Bae
Ro, Jungsil
Semiglazov, Vladimir
Campone, Mario
Ciruelos, Eva
Ferrero, Jean-Marc
Schneeweiss, Andreas
Heeson, Sarah
Clark, Emma
Ross, Graham
Benyunes, Mark C.
Cortes, Javier
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (08): : 724 - 734
[25] Efficacy and safety of neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab in patients with HER2-positive early breast cancer - A retrospective study
Koudsi, L.
Hockaday, C.
Levitt, N.
Tuthill, M.
Roux, R.
Lord, S.
Chiramel, J.
CLINICAL ONCOLOGY, 2025, 38
[26] A cases of pertuzumab plus trastuzumab plus docetaxel was effective for inflammatory breast cancer with HER2-positive
Yamashita, Yuji
Tanaka, Yuko
Nishimura, Meiko
Mukohara, Toru
Kono, Seishi
Takao, Shintaro
Minami, Hironobu
ANNALS OF ONCOLOGY, 2015, 26 : 143 - 143
[27] Change in HER2 status after neoadjuvant chemotherapy (NAC) with trastuzumab and pertuzumab (HP) in patients with HER2-positive early-stage breast cancer.
Ferraro, Emanuela
Razavi, Pedram
Chandarlapaty, Sarat
Modi, Shanu
Wen, Hannah Yong
Brogi, Edi
Norton, Larry
Robson, Mark E.
Dang, Chau T.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[28] Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer
Luo, Yang
Li, Wei
Jiang, Zefei
Zhang, Qingyuan
Wang, Liwei
Mao, Yixiang
Tjan-Heijnen, Vivianne C. G.
Im, Seock-Ah
McConnell, Robin
Bejarano, Sara
Fumagalli, Debora
Bines, Jose
Wang, Bei
Garg, Amit
Kirschbrown, Whitney P.
Xu, Binghe
ANTI-CANCER DRUGS, 2019, 30 (08) : 866 - 872
[29] Real-world study of trastuzumab and pertuzumab combined with chemotherapy in neoadjuvant treatment for patients with HER2-positive breast cancer
Ma, Xiangmin
Zhang, Xiangmei
Zhou, Xinping
Ren, Xiaofei
Ma, Xindi
Zhang, Weifang
Yang, Ruiling
Song, Tao
Liu, Yunjiang
MEDICINE, 2022, 101 (40) : E30892
[30] Retrospective single-center outcome analysis of neoadjuvant and palliative treatment with dual trastuzumab and pertuzumab in HER2-positive breast cancer.
Marhold, Maximilian
Ionce, Lea Roxana
Christ, Alexandra
Aretin, Marie-Bernadette
Sagaster, Verena
Exner, Ruth
Wimmer, Kerstin
Devyatko, Yelena
Fitzal, Florian
Steger, Guenther G.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →